HER2 is a validated target in breast cancer therapy. Two drugs are currently approved for
HER2-positive breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (…

Physiological platelet synthesis is thought to require the humoral activities of meg-CSF and
thrombopoietin, which respectively promote proliferation and maturation of megakaryocytic …

Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse
systemic effects of potent cytotoxic drugs. However, conventional drug conjugation strategies …

Homologous recombination was utilized to generate mice wlth a deletion in the coding
seguence of the nerve growth factor (NGF) gene. Animals homozygous for NGF disruption failed …

The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of
antibody conjugates. To assess the impact of the conjugation site, we engineered cysteines into …

The orphan receptor CRF2-4 is a member of the class II cytokine receptor family (CRF2), which
includes the interferon receptors, the interleukin (IL) 10 receptor, and tissue factor. CRFB4…

Using molecular cloning techniques, human homologs of the known members of the trk
family of neurotrophin receptors have been cloned and sequenced. Overall, there is a high …

Purpose: Antibody drug conjugates (ADCs) combine the ideal properties of both antibodies
and cytotoxic drugs by targeting potent drugs to the antigen-expressing tumor cells, thereby …

Antibody-drug conjugates (ADC), potent cytotoxic drugs covalently linked to antibodies via
chemical linkers, provide a means to increase the effectiveness of chemotherapy by targeting …

Administration of nerve growth factor (NGF) to aged or lesioned animals has been shown to
reverse the atrophy of basal forebrain cholinergic neurons and ameliorate behavioral deficits…